Preclinical Assets Market Report 2026

Preclinical Assets Market Overview

• Preclinical Assets market size has reached to $6.38 billion in 2025 • Expected to grow to $10.2 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: Preclinical Asset Market Growth Through The Mitigation Of Clinical Trial Expenses • Market Trend: AbbVie And Calibr Forge Expanded Strategic Partnership To Advance Preclinical Assets • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Preclinical Assets Market?

A preclinical asset refers to all clinical trial supplies or equipment for preclinical development that encompasses the activities that link drug discovery in the laboratory to the initiation of human clinical trials. This phase precedes human clinical trials and entails essential feasibility assessments, iterative evaluations, and safety data gathering, typically performed on laboratory animals. The main types of preclinical asset services are bioanalysis and DMPK (Drug Metabolism and Pharmacokinetic) studies, toxicology testing, compound management, safety pharmacology, and others. Bioanalysis and DMPK (Drug Metabolism and Pharmacokinetic) studies constitute crucial components of the drug development process, focusing on assessing the pharmacokinetic and drug metabolism characteristics of potential new drugs. The types of models included are patient-derived organoid (PDO) model and the patient-derived xenograft model, which are used by several end users, including biopharmaceutical companies, government institutes, and others.

What Is The Preclinical Assets Market Growth Forecast?

The preclinical assets market size is expected to see strong growth in the next few years. It will grow to $10.2 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing adoption of human-relevant preclinical models, rising demand for accelerated drug development timelines, expansion of personalized medicine pipelines, growing integration of ai in preclinical research, increasing regulatory emphasis on data robustness. Major trends in the forecast period include increasing use of advanced preclinical models, growing adoption of patient-derived xenograft and organoid models, rising demand for integrated preclinical services, expansion of safety and toxicology studies, enhanced focus on translational research.

Global Preclinical Assets Market Segmentation

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services 2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model 3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users Subsegments: 1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development 2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing 3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support 4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations 5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

What Is The Driver Of The Preclinical Assets Market?

The growing need to curb clinical trial costs is expected to propel the growth of the preclinical asset market going forward. Clinical trial costs refer to the expenses associated with planning, conducting, and managing a clinical trial to test the safety, efficacy, and potential benefits of a new medical intervention, such as a drug, medical device, or treatment protocol. These trials provide essential insights into the safety, efficacy, and potential side effects of preclinical assets, helping to validate their therapeutic potential in human subjects. For instance, in February 2023, according to Genetic Engineering and Biotechnology News, a US-based platform that provides the latest information on genetic engineering and biotechnology, developing a new drug among the top 20 global biopharma companies rose by 15%, from $298 million in 2022, to approximately $2.3 billion in 2023, and this includes the costs incurred from developing a drug through clinical trials. Therefore, growing need to curb clinical trial is driving the growth of the preclinical assets industry.

Key Players In The Global Preclinical Assets Market

Major companies operating in the preclinical assets market are Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

Global Preclinical Assets Market Trends and Insights

Major companies operating in the preclinical assets market are focusing on forming strategic alliances to accelerate the discovery and development of innovative drug candidates. These collaborations enable the sharing of research expertise, access to novel targets, and the advancement of early-stage preclinical assets. For instance, in July 2023, AbbVie, a US- based pharmaceutical company, and Calibr, an India-based research, drug development company, announced an expanded strategic collaboration to continue to advance several innovative preclinical and early-stage clinical assets. The partnership is an extension of the collaboration from AbbVie and Scripps Research. Further, Calibr will present AbbVie with a certain number of new discovery targets and preclinical assets of mutual interest for option considerations.

What Are Latest Mergers And Acquisitions In The Preclinical Assets Market?

In August 2024, Otsuka Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, acquired Jnana Therapeutics Inc. for an undisclosed amount. With the acquisition, Otsuka gained access to JNT-517, a potential first-in-class oral treatment for phenylketonuria (PKU), along with Jnana’s specialty and autoimmune pipeline programs and drug discovery technologies. Jnana Therapeutics Inc. is a US-based biotechnology company focused on developing early-stage, preclinical therapeutic candidates.

Regional Outlook

North America was the largest region in the preclinical assets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Preclinical Assets Market?

The preclinical assets market consists of revenues earned by entities by providing preclinical assets services such as process research and development, asymmetric synthesis, safety pharmacology, and custom synthesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The preclinical assets market consists of sales of chemical compounds, biological samples, and sample storage systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Preclinical Assets Market Report 2026?

The preclinical assets market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical assets industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.